Canadian Blood Services warns of imminent shortage of take-home immune globulin drug [Toronto Globe and Mail (Ontario, Canada)]
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK)
Company Research
Source: Toronto Globe and Mail
Canadian Blood Services warns of imminent shortage of take-home immune globulin drug Canadian Blood Services is warning of an imminent shortage of the take-home version of immune globulin (IG), one of the most widely used medications made from human plasma. IG helps to strengthen the immune systems of patients with a variety of genetic conditions that weaken the body’s natural defences against viruses and bacteria. CBS, the national blood authority which is responsible for buying and distributing plasma-derived drugs outside Quebec, issued its first “amber phase advisory” for immune globulin to hospitals across the country last week, prompting a working group of immunologists, neurologists and patient advocates to recommend that, for now, no new patients be started on the self-administered form of the drug. Story continues below advertisement “This is rare,” Harold Kim, chief of the Division of Clinical Immunology and Allergy at Western University in London, Ont., said of the potentia
Show less
Read more
Impact Snapshot
Event Time:
TAK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TAK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TAK alerts
High impacting Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) news events
Weekly update
A roundup of the hottest topics
TAK
News
- Takeda Announces New Assignments of Directors [Yahoo! Finance]Yahoo! Finance
- Takeda Announces New Assignments of DirectorsBusiness Wire
- Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies [Yahoo! Finance]Yahoo! Finance
- Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV TherapiesBusiness Wire
- Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia [Yahoo! Finance]Yahoo! Finance
TAK
Sec Filings
- 6/28/24 - Form 424B2
- 6/28/24 - Form FWP
- 6/27/24 - Form 424B5
- TAK's page on the SEC website